Enterprise Value
2.04B
Cash
322.6M
Avg Qtr Burn
-15.83M
Short % of Float
7.58%
Insider Ownership
1.18%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Phase 3 Data readout | ||
Rusfertide (PTG-300) (Hepcidin Mimetic) Details Blood cancer, Polycythemia vera, Cancer | Phase 3 Data readout | |
JNJ-2113 (PN-235) (Oral IL-23 receptor antagonist) Details Ulcerative colitis | Phase 2b Data readout | |
Rusfertide (PTG-300) (Hepcidin Mimetic) Details Genetic disorder, Rare genetic disease | Failed Discontinued | |
PTG-200 (IL-23R Antagonist) Details Crohns disease, Inflammatory bowel disease, Inflammatory disease | Failed Discontinued | |
PN-943 (α4β7-Integrin Antagonist) Details Inflammatory bowel disease, Inflammatory disease | Failed Discontinued |